Arun J. Sanyal
@ArunJSanyalVCU
Followers
575
Following
88
Media
47
Statuses
280
The views expressed here do not necessarily reflect those of VCU or its medical school or the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.
RVA liver lover since 1989.
Joined August 2023
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
FEMA
• 1265763 Tweets
#LISAxMoonlitFloor
• 267462 Tweets
Liz Cheney
• 265829 Tweets
JUMP
• 206416 Tweets
MOONLIT FLOOR OUT NOW
• 201878 Tweets
Mets
• 152280 Tweets
Baker
• 60878 Tweets
Falcons
• 57384 Tweets
Brewers
• 56115 Tweets
天使の日
• 43332 Tweets
Pete Alonso
• 42815 Tweets
SAFE FLIGHT JESBIBLE
• 28345 Tweets
Bucs
• 25478 Tweets
Spiritual Awakening
• 20931 Tweets
Phillies
• 20845 Tweets
Bijan
• 20823 Tweets
Kirk Cousins
• 19849 Tweets
Mooney
• 16451 Tweets
Mike Evans
• 15873 Tweets
ワートリ
• 12283 Tweets
#TBvsATL
• 11064 Tweets
We're thrilled to have
@juanpabloarab
join our team to push our alcohol-related liver disease research to the next level. Learn more about him at
#livertwitter
11
10
116
Honored to have my contributions to the field of
#hepatology
recognized and to be included among the top cited 🌐 Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List
#livertwitter
12
5
109
What an incredible
#EASLCongress
in Milan! So much to take in, so much to discuss about
#MASH
. We will continue at
@AASLDtweets
#TLM
in San Diego.
#livertwitter
@EASLnews
1
5
56
Exciting news in
@HEPJournal
: MASEF Score, based on combination of serum-based metabolomics and clinical data and developed by
@OWLMetabolomics
, can accurately identify
#MASLD
with ≥F2 fibrosis (at-risk MASH)
#livertwitter
@NoureddinMD
@RMayo_OWL
2
11
50
Thrilled to learn of the election of
@jasmohanbajaj
to the Association of American Physicians! See the entire list of honorees at
#livertwitter
9
3
48
🆕REVIEW: Digital pathology and artificial intelligence in non-alcoholic steatohepatitis
➡️Current status and future directions. Read it here👉 via
@JHepatology
#LiverTwitter
1
11
43
A major milestone for our
#liver
patients and for the field. As an investigator working on MASH, I congratulate
@MadrigalPharma
& the communities of my colleagues and patients who participated in the treatment trials to make approved therapy for
#MASH
a reality.
#livertwitter
#BREAKING
It is a big day for the Liver Community! Madrigal is proud to announce the first and only
@US_FDA
-approved therapy in NASH/MASH. Learn more here:
#FDAApproval
#NASH
0
65
190
0
6
36
Great 📰 2 share in liver disease diagnosis! Our latest
@FNIH_Org
NIMBLE results in
@NatureMedicine
. Noninvasive blood tests could revolutionize
#NASH
/
#MASH
diagnosis, care & reduce the need for biopsies.
#LiverTwitter
#ParisNASHMeeting
@VCU
@VCUHealth
2
14
34
New Review in
@NatureMedicine
: Our call for inclusion of patients with
#MASLD
and measurement of liver outcomes in cardio-kidney-metabolic trials, when data suggest benefits and safety.
@FaiezZANNAD
@JavedButler1
#livertwitter
0
10
34
One of my favorite moments at
#EASLCongress
is when I get to greet the next generation of hepatologists/gastroenterologists at the conference. Caught up with
#VCU
SOM resident
@ianpoconnor
at his poster on
#MASH
.
#livertwitter
@EASLnews
@jasmohanbajaj
0
2
33
The newest member of our team,
@juanpabloarab
Bringing up the nomenclature change as well as our
#livertwitter
focus on
#ALD
at the
@NIAAAnews
advisory council
@juanpabloarab
@AASLDtweets
@NIH
0
3
26
2
1
28
Thanks,
@HealioGastro
, for the opportunity to share my perspective on this topic of
#GLP1s
for the treatment of
#MASH
with such distinguished colleagues.
#livertwitter
@DrLoomba
@scottisaacsmd
In this month’s
@GoHealio
#GI
Exclusive,
✌🏻
#hepatologists
and ✌🏻
#endocrinologists
provide perspectives on the use of
#GLP1s
for the treatment of
#MASH
, while
@ZobairYounossi
shares his insights in a guest editorial.
Check it out 🔽🔽
0
2
2
2
3
29
With its anti-fibrotic benefits, pegozafermin has potential to help compensated cirrhotic
#MASH
patients and reduce the risk of decompensation. I look forward to evaluating the potential benefits of pegozafermin in ENLIGHTEN-Cirrhosis.
#livertwitter
1
4
27
Thrilled that pediatric hepatologist
@SaulKarpen
joins the institute as our first chief scientific officer. He will help accelerate the science needed to bring preventive & therapeutic strategies across patients' life cycles.
#livertwitter
@AASLDtweets
2
3
27
Arriving 🛬 for
@EASLnews
#EASLCongress
later today. Looking forward to an exciting meeting of research discoveries, treatment news, networking and, of course, some wonderful Italian food! 🍝
#livertwitter
0
1
26
A successful inaugural
#MASH
School! Thanks to my many
@VCU
colleagues who presented to our guests, all top hepatologists from Brazil. And to CEO
@Avant_Sante
S. Yarramraju, who joined us in discussing
#liverhealth
.
#livertwitter
@saulkarpen
@RichSterlingMD
@usponline
4
1
25
Here's why I love the liver:
The liver is an underappreciated organ and is almost always overshadowed by the heart and the brain.
Really, it is the undervalued, unsung hero in our body! Did you know that this remarkable organ performs over 500 vital tasks, integral to our survival and well-being? While a
0
5
14
0
1
24
Enjoyed my conversation with 89bio CEO Rohan Palekar for the podcast 'Breakthroughs in
#MASH
' podcast. Take a listen👂 at
#livertwitter
0
2
24
Looking forward to colleague M. Shadab Siddiqui's presentation tomorrow at Paris
@NASHmeeting
on 'Challenges and opportunities in development of therapeutics for NASH after Liver transplantation.' 🗼
#ParisNASHMeeting
#LiverTwitter
#livertransplant
0
1
22
Thrilled that
@VCU
,
@saulkarpen
and our colleague M.S. Siddiqui could be part of this collaboration. Empowering Young Medics in
#Liver
Research: Indo-US Initiative via
@timesofindia
#liverwiter
1
3
23
I appreciated the opportunity from
@Nature
to discuss the approval last week of
#resmetirom
and the future of treatments for liver disease.
NASH field celebrates ‘hurrah moment’ with 1st
@US_FDA
drug approval for the disease.
@ArunJSanyalVCU
tells
@Nature
"fantastic to be able to tell your patients, yes, there is a drug that potentially can be used and is approved."
#liver
#livertwitter
0
4
16
0
2
22
On this Global Fatty Liver Day, I'm excited to share a conversation I had with
@GlobalLiver
's
@JeffJMcIntyre
on the importance of screening and how we can help develop better treatments for patients. 👀 our discussion at
#livertwitter
#FattyLiverDay
0
2
22
As many of you know, nurturing the next-gen of HEP is dear to my heart. I want to congratulate our own Madison Nguyen, a rising third year resident at
#VCU
SOM, for her selection as an
@AASLD
Emerging
#Liver
Scholar for 2024.
#livertwitter
0
0
22
Hopeful that we will soon have
@US_FDA
approval of the first therapy to treat NASH ...
Brilliant new study on drug treatment of non-alcoholic fatty liver disease
A new drug called Resmetirom has been shown to reduce both liver scarring and inflammation compared to no treatment in patients with biopsy proven non-alcoholic severe fatty liver
29
131
746
0
2
22
New insights into liver fibrosis in
@LiverInt
! SHG/TPEF microscopy with
#AI
offers precise assessment of
#fibrosis
in MASH F3 patients, revealing changes even when standard scoring shows 'no change.'
#livertwitter
@DavidKleiner12
0
6
21
Thanks to
@JVLazarus
and
@ISGLOBALorg
for the opportunity to bring attention to this global public health threat.
Our second panel discussion at UNGA side event today in NYC: Jeffrey Lazarus, Head of public health liver group, ISGlobal; professor of global health, CUNY SPH; chair, Healthy Livers Healthy Lives Coalition: “The new nomenclature makes it easier to engage with Health care
0
4
12
0
2
21
Excited to see the 👀 to this tragically📈 trend in liver health. We need more global support for research to make a significant difference in treatment to improve the lives of millions with
#liver
disease.
📢Our September issue is out ‼️
Featured article:
➡️A global research priority agenda to advance
#publichealth
responses to
#fattyliver
disease
Full issue➡️
2
27
66
0
5
19
.
@JasmohanBajaj
and I look so young ... our older and hopefully wiser selves are looking forward to the conference.
INASL- 2024
7th - 10th August, 2024
Kochi, Kerala, India
Register Now.
1
3
12
2
0
21
Kenneth Cusi of
@UFEndocrinology
in a
@NEJM
editorial called Phase 3
#NASH
resmetirom trial results "encouraging." 👀 Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
#livertwitter
@MadrigalPharma
@Pinnacle_TX
#MAESTRO
-NASH
0
4
19
I truly enjoyed the opportunity to visit with colleagues at
@NUSingapore
last week to celebrate an MOU that will deepen the relations between our institutions and develop a formal channel to advance liver research.
#livertwitter
@AASLDtweets
@APASLnews
0
0
19
On Friday, I'll present on Metabolomics and lipodomics in
#MASH
, and my
@VCU
colleague
@JasmohanBajaj
on Microbiome in MASH pathogenesis, at
@AASLDtweets
Emerging Topic Conference: Precision Medicine in
#MASLD
in Las Vegas! Hope to see you there.
#LiverTwitter
#liver
0
0
18
Congratulations to the MAESTRO-NASH study team! We've been anticipating this publication since the 2023 EASL Congress.
The most anticipated results of 2024: NASH resolution in 30%, fibrosis improvement in 25%
Resmetirom trial out now in
@NEJM
#livertwitter
Thyroid hormone receptor beta agonist for fibrosis F1-F3
2
42
94
1
2
19
I'll be there. Looking forward to seeing many colleagues and hearing about their research.
🚨Have you registered to EASL Congress 2024?
On 5-8 June, our hepatology community will convene in Milan, Italy and online, at the largest European Congress for liver disease.
Join us to stay up to date with research, meet colleagues, and discover something new in your field!
0
3
7
0
4
18
Pilot study: Testosterone Prodrug Improves Muscle Mass,
#HE
in Men With
#Cirrhosis
via
@Medpage
#livertwitter
0
4
17
I'll speak in just a few hours at the EASL
#SLDSummit
on "MASH cirrhosis: the challenges of diagnosis, prognosis and treatment."
@EASLnews
#Livertwitter
#MASH
#NASH
🌟 Excitement is in the air as we kick off the
#SLDSummit
2023 in beautiful Prague and online!
Join us for the Welcome Session featuring inspiring opening remarks by our organisers
@lotersztajn
@FrancqueSven
and
@JVLazarus
. 🌍
Remember to use the hashtag
#SLDSummit
and stay
0
10
26
0
1
16
You're very kind. I enjoyed the visit and the opportunity to discuss the status of the
#MASLD
field.
Amazing
@ArunJSanyalVCU
delivered the Schwartz-Graham professorship lecture: A tale of 25+ year journey about MASLD by a legend in the field
@VCU_Liver
@BCMDeptMedicine
@KanwalFasiha
1
5
11
0
3
16
In
@TheLancet
: GLP-1 receptor agonists, such as semaglutide, could curb both health & economic effects of obesity.
In a Viewpoint, authors analyse GLP-1 receptor agonist coverage policies in 13 high-income countries to draw lessons for policy development:
0
2
16
Appreciate the
@FattyLiverA
summaries from the meeting, especially useful for those unable to attend
#MASLD
#AASLDETC
#livertwitter
Arun Sanyal presents “Metabolomics and Lipidomics in MASLD”.
“We need to think about “the metabolome and metabolic health”.
Summary:
• Metabolomic studies reveal a widespread disruption of metabolic pathways in the liver in MASLD
• Key pathways likely to play a biologically
0
3
7
1
1
16
This
#WorldLiverDay
, liver physicians and many patients can be thankful for the recent FDA approval of the first drug to treat
#MASH
. Here's why I love the
#liver
and hope you do, too.
#livertwitter
0
0
16
Very proud to see these fine efforts.
So happy and proud to see
@VCUHealth
trainees from Grad Students, Medical students and fellows present
@DDWMeeting
#DDW2024
@VAResearch
@VCU_Liver
@RichmondVAMC
#alcohol
#cirrhosis
#SBP
@RichSterlingMD
@ArunJSanyalVCU
@nurs605
0
1
34
0
0
16
Thankful to my Richmond area colleagues for the honor.
🎉 👏 We're very proud of our institute faculty who were named to the 2024 "Top Docs" list by their health care colleagues in Richmond Magazine!
@ArunJSanyalVCU
@RichSterlingMD
@VCUTransplant
#livertwitter
#liverhealth
0
0
7
1
1
15
Gracias a Mexico
Día 1 de
#NASHWeek
@incmnszmx
Gracias a todos!!
@ArunJSanyalVCU
@nagachalasani
@rajVuppaLanchi
@craiglammertIU
@tshamah1
@NayelliCointa
@OWLMetabolomics
@IUGastro
@VCU_Liver
@RajuAvantSante
1
6
38
0
1
15
Want to know what our
@VCU_Liver
researchers are presenting at American Association for the Study of Liver Diseases (AASLD)
#TLM2023
? Check out our collected abstracts.
0
2
14
Some very important research by our
@JasmohanBajaj
that should give you pause to consider how we treat these patients.
In 2 national data sets of >11,000 patients with SBP
SecSBPPr was prescribed in roughly half of patients.
When initiated, SecSBPPr, compared to no prophylaxis after SBP 🔼 risk of SBP recurrence in multivariable analysis by 63-68%, and this trend worsened over time
0
0
5
0
2
14
Happy to see everyone and participate in
@INASL_Liver
2024!
@DrLoomba
congratulation on this award- very well deserved amazing to witnesses this in India, Kerala, beautiful Kochi.
Impressive journey!!
Great meeting by
@INASL_Liver
@ajay_duseja
- honoured to represent
@EASLnews
and support the impressive Indian hepatology community
1
5
30
0
0
13
Article in press
@JHepatology
by
@VCU_Liver
researchers and our
@NUSingapore
colleagues. Natural history of# NASH
#cirrhosis
in
#livertransplant
waitlist registrants.
@WenHuiLim4
@AASLDtweets
#LiverTwitter
1
1
13
Folic acid has also been shown to slow
#NASH
/
#MASH
progression and reverse
#liver
inflammation and fibrosis.
Having enough folic acid in your body before & during pregnancy can help prevent major birth defects. Whether you get it from fortified foods or supplements, aim to get 400 mcg of folic acid every day. Learn how to plan for your ideal pregnancy & birth ➡️
0
0
0
0
2
11
Looking forward to participating in this
@economistimpact
via
@ISGLOBALorg
presentation.
MASLD and MASH are liver conditions that require action: from the individual, health systems and society at large. Read
+ join us on 23 Sept 2024 at the first UN General Assembly MASH side-event, convened by
@economistimpact
via
@ISGLOBALorg
.
#LiverTwitter
1
13
33
0
2
13
Thanks to
@statnews
and
@elaineywchen
for the opportunity to weigh in. Fibrosis regression (and maintaining muscle mass) remains our goal for
#liver
#MASH
.
Researchers are looking at the obesity drugs in development as a way of addressing the fatty liver disease MASH.
1
0
2
0
1
11
I appreciated the opportunity to appear in a
#HistoIndex
webcast on the role of biopsies in
#MASH
clinical trials & patient management post-drug approval. Thanks to Nikolai Naoumov,
@DavidKleiner12
&
@TimKendall_Path
for the great convo.
#livertwitter
1
1
12
Looking forward to the visit with your center.
This Thursday at 4PM CST, the
#TMC
#DDC
welcomes
@ArunJSanyalVCU
for our seminar! 👏
With a strong clinical
#hepatology
background, Dr. Sanyal will review the limitations and best practices for noninvasive tests in
#MASLD
patients. 🥼
Join us in person
@bcmhouston
or via Zoom⤵️
0
1
1
1
3
12
If we are to really tackle
#NAFLD
, we need research like this to understand the full burden of the disease so that we can promote a global research priority agenda to advance public health responses.
@JVLazarus
#LiverTwitter
@EASLnews
@JHepatology
1
0
12
Good overview for primary docs of treatment options, including GLP-1 receptor agonists, in development for
#MASH
from the Second Annual NAFLD & NASH Primary Care Summit. Presented by Dr. Stephen Harrison. 👀
@AASLDtweets
@MadrigalPharma
#livertwitter
0
1
12
Original Article: Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
#EASLCongress
|
@EASLnews
1
56
186
0
1
10
Very excited to join forces to revolutionize liver health with
@OWLMetabolomics
.
We've partnered with
@VCU_Liver
to advance scientific research. Combining our metabolomic expertise with their renowned work, we're set to make significant strides in healthcare.
🔗 Dive into the details in our press release:
1
2
8
1
2
11
I appreciate the hospitality from
#NASHWeek2024
and your colleagues in Mexico.
Tuvimos la fortuna de contar con el Dr
@ArunJSanyalVCU
de
@VCU_Liver
en
#NASHWeek2024
quien participó en varios paneles de discusión y casos clínicos.
Además nos dio una plática magistral sobre tratamientos actuales y futuros en
#MASLD
y fibrosis.
@incmnszmx
0
2
16
0
2
11
I will speak Sept. 21 at the EASL
#SLDSummit
on "MASH cirrhosis: the challenges of diagnosis, prognosis and treatment."
@EASLnews
#Livertwitter
#MASH
#NASH
🔬The EASL
#SLDSummit
presentations will explore every facet of Steatotic Liver Disease. From emerging therapies to diagnostic innovations, this summit promises to deepen your knowledge and drive progress in the field!
Be a part of it! Standard registration closes on 20
0
5
13
0
1
11
This publication highlights the need to treat
#MASH
/
#NASH
more holistically, taking into account the competing threats to life from mainly cardiometabolic and hepatic risks.
#livertwitter
@NatureComms
@MayoClinic
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis | Nature Communications
0
0
0
1
4
10
This reiterates the importance of maintaining muscle mass among our liver patients.
Can we⬇️
#sarcopenia
with a capsule in
#cirrhosis
? Yes!
#gutmuscleaxis
#gutbrainaxis
In
#RIVET
RCT w
#rifamycinSVMMX
,we found
🔑⬆️handgrip,💪mass & physical well-being
How? Altered
#microbiota
function w⬆️butyrate, ⬆️active
#androgens
&⬇️
#ammonia
Read⤵️
2
31
90
0
1
10
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial -
@LancetGastroHep
#NAFLD
#livertwitter
1
0
10
Via
@HealioGastro
at
@EASLCongress
: 🔑takeaways for
#tirzepatide
in
#MASH
:
👉🏻More patients on tirzepatide saw resolution w/o worsening of
#fibrosis
(43.6% on 5mg, 55.5% on 10mg and 62.4% on 15mg vs. 9.8%).
👉🏻Up to 55% saw improved fibrosis
#livertwitter
0
2
9
@JVLazarus
@AlinaAllenMD
@AASLDtweets
@VCU_Liver
@NoureddinMD
@AlkhouriNaim
@marurinella
@DrLoomba
@scottisaacsmd
@Mayo_liverdoc
@schattenbergJ
@AleksanderKrag
@NASH_and_coffee
@mcharltonmd
@MajaThiele
@capicchio
@ajay_duseja
@MarcoArreseMD
@juanpabloarab
@Aurorabbelles
A very engaging discussion!
1
0
9
A r randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis:
@Hep_Journal
0
1
9
Thanks to
@healiogastro
for covering my presentation on this important issue as we seek new treatments for
#cirrhosis
and
#MAFLD
.
#ICYMI
❗❗
👉🏻At week 2️⃣4️⃣,
#LPCN1148
significantly improved the Skeletal Muscle Index at L3 vs. placebo.
👉🏻This improvement was maintained through 5️⃣2️⃣ weeks of treatment.
#EASLCongress
🔽🔽
0
0
0
1
1
9
Pleased to hear the news about
@VCU
, my home for the past 4 decades, in
@usnews
latest rankings. The university's reputation for
#innovation
and impactful
#research
to address global problems is growing rapidly.
#LiverTwitter
0
0
9
🙏🏽
0
0
8
Looking forward to the conclave with so many distinguished colleagues.
Save the date ! We are back with the 7th edition of the NAFLD ➡️ MASLD Conclave .
@VCU_Liver
@GChoudhuri
@INASL_Liver
@ajay_duseja
@wadhawan_manav
@DrKaushalMadan1
@neerajsaraf
@DrAshish_Kumar
1
4
15
0
1
8
Appreciate the coverage of our work by
@AGA_GIHN
.
A study presented by
@DrLoomba
at
#EASLCongress
found Tirzepatide was effective in MASH resolution and improving fibrosis.
“These are convincing results in terms of MASH resolution, showing a strong response and dose-dependence,”
@FrancqueSven
commented.
0
0
1
0
0
8
Glad to see so many colleagues responding to the need for NITs.
@AlinaAllenMD
@AASLDtweets
@VCU_Liver
@NoureddinMD
@AlkhouriNaim
@marurinella
@DrLoomba
@scottisaacsmd
@Mayo_liverdoc
@schattenbergJ
@AleksanderKrag
A full house for this amazing NIT panel discussion at
#TLM23
#LiverTwitter
1
3
16
0
0
8
Thanks to the
@FattyLiverA
for capturing my comments at yesterday's events. Greatly appreciated.
A great analogy by
@ArunJSanyalVCU
from the United Nations General Assembly side event speaking about how MASLD and MASH are so interrelated with all the metabolic disorders. We can no longer see the liver in isolation.
“You know, having talked to colleagues from the obesity
1
3
16
2
2
13
More on
#survodutide
in
@JHepatology
: Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in
#cirrhosis
#livertwitter
0
1
8
Exciting work ... now I'm hungry for a burger.
🔑Are all proteins🟰 for ammoniagenesis? No!
🔑Can one meal change affect ⬇️
#ammonia
in
#cirrhosis
? Yes!
✅our
#RCT
where 1⃣ meal change from 🥩to 🌱/🌿-based was enough to⬇️
#ammonia
!
🔑Impt because replacing full diets⛔️
🔑metabolomic changes
@ACG_CTG
⤵️
2
26
79
0
1
7
Led by Margery Connelly of
@LABCORP
, we report in
@HepCommJournal
that the clinical performance of NIS2+™ supports the use of this blood-based test to diagnose at-risk
#NASH
in older adults.
@AASLDtweets
0
0
7
This important research by my colleague
@JasmohanBajaj
has a valuable lesson for clinicians: Be sure to consider the
#liver
when you're evaluating your patients.
@aafp
#liverhealth
@livertwitter
Among veterans with a diagnosis of dementia, a high Fibrosis-4 score suggestive of advanced liver fibrosis to cirrhosis was observed in 5-10% of the patients who previously did not have a diagnosis of cirrhosis.
@jasmohanbajaj
@VeteransHealth
0
4
6
0
1
7
One of our Class of 2024! Congratulations,
@bryan_badal
!
Congratulations
@bryan_badal
for Outstanding trainee research project
@AmCollegeGastro
#ACG2023
on
#cirrhosis
#ammonia
and impact of meat alternatives for
#hepaticencephalopathy
#proudmentor
. supported by
#ACGinstitute
clinical research award. ✅it out in the Liver Plenary!
2
4
45
0
0
7
At an
@FDA
workshop yesterday, I was privileged to provide an update on the
@FNIH_Org
NIMBLE project and noninvasive tests for
#NAFLD
. I would like to thank the many patients who allowed us to study them, without whom none of this work would be possible. Thank you.
#LiverTwitter
0
1
6
I'm
@ArunJSanyalVCU
and I approve this message.
#get2knowyourliver
. October is Liver Awareness Month.
#LiverTwitter
#fattyliver
#NASH
#MASH
@AASLDtweets
@GlobalLiver
@LiverSaver
@liverUSA
0
0
7
New data from
#EASLCongress
showed:
Recurrence of
#hepaticencephalopathy
was lower among patients with
#cirrhosis
and HE who received oral capsule 💊 or enema
#FMT
💩 vs. placebo.
Learn more
@EASLnews
🔽🔽
0
5
10
0
0
7
@INASL_Liver
@ajay_duseja
@shivaramsingh
@VCU_Liver
We're very much looking forward to seeing our friends at
@INASL_Liver
, West Bengal and the Martin Centre for 2 busy days of presentations.
@JasmohanBajaj
@saulkarpen
0
1
7
Expect a great panel discussion Friday @ session w/
@VCU_Liver
colleague
@JasmohanBajaj
and others on Multi-omic Approaches to Unraveling MASLD at
@AASLD
Precision Medicine in
#MASLD
.
@AASLDtweets
#livertwitter
0
0
6
Glad to see that this work by
@bryan_badal
and
@JasmohanBajaj
is recognized for its potential impact.
According to
@JasmohanBajaj
from
#ACG2023
:
Substituting just one meat-based meal 🥩 with protein from plant 🥦 or dairy 🥛 sources could improve metabolite signatures linked to
#hepaticencephalopathy
in patients with
#cirrhosis
.
🔽🔽
0
4
7
0
1
6
A great honor to host
@DavidKleiner12
here at
@VCU_Liver
. Thanks for joining us, and thanks to those who joined us for an enlightening presentation on a Friday afternoon.
Thrilled to host
@DavidKleiner12
, reference pathologist for the
@NIDDKgov
sponsored DILIN, on Friday. Dr. Kleiner spoke on “The Pathology of Steatotic Liver Disease – Lessons from the
#NASH
CRN.” He participates in 2 multicenter clinical networks focused on
#NAFLD
.
#LiverTwitter
0
0
15
0
0
6
@JasmohanBajaj
@AASLDtweets
@MeenaBBansal
@DrLoomba
@SanjayaSatapath
@ArpanPatelMD
@MonikaSarkarMD
@ndshah85
@AparnaGoelMD
@BinitaKamath
@ajay_duseja
@AASLDPresident
@norahterrault
What a wonderful celebratory group!
0
0
6
We're very proud of our current and former trainees at
@VCU_Liver
.
Excited to present data w current trainees & former trainees/current colleagues on
#cirrhosis
#hepaticencephalopathy
#sweatsensors
#dementia
@AASLDtweets
#TLM23
@VCU_Liver
@VAResearch
@nilangpatel
@VCU_CCTR
#NACSELD
0
1
36
0
0
6
Thrilled to host
@jrcolca
for in-depth discussions on
#NASH
and metabolic health, and brainstorm future collaborations with Cirius Therapeutics. Jerry toured our biorepository lab, where we've stored the nearly 8,000 samples donated by Cirius last fall.
#livertwitter
#diabetes
0
0
6
Thanks for sharing.
Finally something (androgen agonism in men) for the advanced phenotype of cirrhosis - improved sarcopenia and multiple clinically relevant metrics - good proof to further advance
0
1
10
0
0
5
See you there!
The Hybrid Paris
#Hepatology
Conference is taking place March 18-19. Learn more about the conference and register online at .
0
1
13
0
0
6
Deepest thanks to
@jrcolca
and Cirius Therapeutics for this major boost toward establishing our biorepository as an international resource for liver research, to uncover life-changing therapeutic breakthroughs & get them to patients sooner.
#livertwitter
0
0
5
Congratulations,
@ObiAseemMDPhD
!
Our
@ObiAseemMDPhD
recently was awarded a grant from
@PSCPartners
to further his research on whether RUNX1 directly makes bile duct cells produce more inflammatory substances and how these substances attract immune cells. ➡️ new treatments?
0
1
5
0
0
5
Use a translator to read the article, but we're very excited by this news!
Faculdade de Medicina da Virginia Commonwealth University (E.U.A) em novo acordo acadêmico 2024
🎓📚♻️✨
0
0
7
0
0
5
Pleased for the opportunity to work with
@NIAAAnews
Laboratory of Neurogenetics on "A patient-based iPSC-derived hepatocyte model of alcohol-associated
#cirrhosis
reveals bioenergetic insights into disease pathogenesis," now in
@NatureComms
.
#livertwitter
0
1
5
1+ 1 = 3
Lactulose + Rifaximin = Reduced episodes of hepatic encephalopathy
@HepCommJournal
4
77
298
0
0
5
Our
@radiology_rsna
NIMBLE study defines expected US elastography measurement variability to guide clinical interpretation, enable diagnostic enrichment in clinical trials, and support FDA biomarker validation for
#MASLD
.
@UWRadiology
@MGHImaging
@MGH_RI
0
2
6
.
@FPetersenA
, secretary of health for
@GobiernoJalisco
, thanks
@Etcurae
,
@Avant_Sante
and
@VCU_Liver
for recognizing
@saludjalisco
efforts to promote research into metabolic disease, which affects many adults in Mexico and Jalisco.
#livertwitter
0
1
3
@EliLillyandCo
says the tirzepatide study met its primary endpoint where up to 74% of participants achieved an absence of
#MASH
with no worsening of fibrosis at 52 weeks, compared to nearly 13% of participants on placebo.
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data.
0
4
18
0
1
4
We'll be there!
Colleagues, TLM registration for AASLD members opens tomorrow! Renew your membership to stay connected with hepatology leaders around the world, and best-in-class member benefits.
0
5
21
0
0
4
Congratulations!
Today, we've announced
@NEJM
published the primary results of our pivotal Phase 3 MAESTRO-NASH trial. We hope the publication will serve as a catalyst for
#NASH
research and help advance care for patients with this serious
#LiverDisease
.
1
7
15
0
0
4
"(T)he clinical trial landscape for chronic diseases must also evolve to allow treatments to be tested for more than one disease at a time, in unique development programs aiming to evaluate multi-organ benefits for regulatory approval purposes based on appropriate endpoints."
@FaiezZANNAD
& colleagues call for inclusion of patients with
#MASLD
and measurement of liver outcomes in cardio-kidney-metabolic trials, when data suggest benefits and safety — and discuss issues around trial design & regulatory approval.
@ArunJSanyalVCU
0
0
1
0
0
4